Inhibikase Therapeutics, Inc. Common Stock vs. Moderna, Inc. Common Stock
IKT
Inhibikase Therapeutics, Inc. Common Stock
$2.23 -3.26%
VS MRNAModerna, Inc. Common Stock
$154.04 -2.55%
Moderna, Inc. Common Stock (MRNA) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| IKT | MRNA | |
|---|---|---|
| Market Cap | $320.93 million | $61.50 billion |
| Revenue (TTM) | $3.72 million | $2.23 billion |
| Net Income (TTM) | $-60,637,002 | $-3,151,000,000 |
MRNA leads on 2 of 3 size & scale factors.
Valuation
| IKT | MRNA | |
|---|---|---|
| Price / Book | 2.09 | 9.10 |
| Price / Sales | 86.39 | 27.60 |
IKT and MRNA split the valuation factors evenly.
Profitability
| IKT | MRNA | |
|---|---|---|
| Net Margin | -1632.18% | -141.43% |
| Return on Equity | -39.55% | -46.61% |
IKT and MRNA split the profitability factors evenly.
Risk & Sentiment
| IKT | MRNA | |
|---|---|---|
| Short Interest | 0.02% | 0.01% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: IKT overview, IKT financials, MRNA overview, MRNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.